|
06.01.2014 17:45:00
|
STENTYS : Agenda of Financial Events 2014
Regulatory News :
STENTYS (Paris:STNT) (FR0010949404 – STNT), a medical technology company commercializing the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), announced today its preliminary financial agenda for 2014.
| Event | Date * | |
| Q4 Full Year Sales 2013 | Thursday, January 23, 2014 | |
| Full-Year Results 2013 | Thursday, March 13, 2014 | |
| Q1 Sales 2014 | Thursday, April 24, 2014 | |
| Q2 Sales 2014 | Thursday, July 24, 2014 | |
| Half-Year Results 2014 | Thursday, August 28, 2014 | |
| Q3 Sales 2014 | Thursday, October 23, 2014 | |
|
Financial year ended 31 December |
* Subject to modification. Press releases are distributed after the financial markets closure.
About STENTYS:
STENTYS is developing and commercializing
innovative solutions for the treatment of patients with acute myocardial
infarction (AMI, or heart attack) and complex coronary artery disease.
STENTYS’s Self-Apposing® Stents are designed to adapt to
vessels with ambiguous or fluctuating diameters, particularly in the
post-infarction phase, in order to prevent the malapposition problems
associated with conventional stents. In the APPOSITION III clinical
trial, STENTYS stents demonstrated a very low one year mortality rate
among 1,000 high-risk AMI patients when compared to recent studies with
conventional stents. More information is available at www.stentys.com.
STENTYS is listed on Compartment C of the NYSE Euronext Paris
ISIN:
FR0010949404 – Ticker: STNT
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu STENTYSmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu STENTYSmehr Analysen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.